In several European countries, land use changes can be analysed on the basis of the Franciscan Cadastre. Present land use data is defined on the basis of orthophotos, but the historical data is ...available only at a parcel level. Therefore, a question arose as to how reliable results about land use changes can be. The main aim of the paper was to analyse land use dynamics with the Franciscan Cadastre and to test the compatibility of detailed and parcel level of modern data. The study was carried out by calculating land use structure and landscape metrics for a part of the Pannonian low-hills area in Slovenia. We have observed that the calculation of the land use type structure mostly provided similar results regardless of the level of detail. On the other hand, the results of landscape metrics analysis were highly affected by the level of detail. The analysis at the parcel level showed that the forest area expanded, and fields and vineyards areas diminished. In general, today’s landscape is made of less patches, but they are larger and of more irregular shapes. We can conclude that a comparison of modern data and historical data based on Franciscan Cadastre must include generalisation to a parcel level.
U nekoliko srednjeeuropskih država promjene uporabe zemljišta mogu se analizirati na temelju Franciskanskog katastra. Glavni je cilj članka analizirati dinamiku uporabe zemljišta uz pomoć ...Franciskanskog katastra i suvremenih podataka o uporabi zemljišta. Studija je provedena na temelju izračuna strukture uporabe zemljišta i metrike krajolika za dio regije Slovenske Gorice u Sloveniji. Analiza je pokazala da je šumska površina proširena, a da su površine s oranicama i vinogradima smanjene. Današnji je krajolik općenito sastavljen od manjeg broja zakrpa, ali su oni veći i nepravilnijih oblika.
In several Central European countries, land use changes can be analysed on the basis of the Franciscan Cadastre. The main aim of the paper was to analyse land use dynamics with the Franciscan ...Cadastre and modern land use data. The study was carried out by calculating land use structure and landscape metrics for a part of Slovenske Gorice region in Slovenia. The analysis showed that the forest area expanded, and fields and vineyards areas diminished. In general, today’s landscape is made of less patches, but they are larger and of more irregular shapes.
From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in primary antiphospholipid syndrome (p-APS) and (2) determine their prognostic ...value.
This retrospective French multicenter cohort study included all patients diagnosed with p-APS (Sydney criteria) between January 2012 and January 2019. We used Kaplan-Meier and adjusted Cox proportional hazards models to compare the incidence of relapse in p-APS with and without non-criteria manifestations.
One hundred and seventy-nine patients with p-APS were included during the study time, with a median age of 52.50 years 39.0; 65.25 and mainly women (n = 112; 62.6%). Among them, forty-three patients (24.0%) presented at least one non-criteria manifestation during the follow-up: autoimmune cytopenias (n = 17; 39.5%), Libman Sachs endocarditis (n = 5; 11.6%), APS nephropathy (n = 4; 9.3%), livedo reticularis (n = 8; 18.6%), and neurological manifestations (n = 12; 27.9%). In comparison to p-APS without any non-criteria manifestations (n = 136), p-APS with non-criteria features had more arterial thrombosis (n = 24; 55.8% vs n = 48; 35.3%; p = 0.027) and more frequent pre-eclampsia (n = 6; 14.3% vs n = 4; 3.1%; p = 0.02). The prevalence of triple positivity was significantly increased in patients with non-criteria features (n = 20; 47.6% vs n = 25; 19.8%; p = 0.001). Patients with p-APS and non-criteria manifestations (n = 43) received significantly more additional therapies combined with vitamin K antagonists and/or antiaggregants. Catastrophic APS (CAPS) tended to be more frequent in p-APS with non-criteria features (n = 2; 5.1% vs none; p = 0.074). The p-APS with non-criteria manifestations had significantly increased rates of relapse (n = 20; 58.8% vs 33; 33.7%; p = 0.018) in bivariate analysis, but in survival analyses, the hazard ratio (HR) of relapse was not significantly different between the two groups (HR at 1.34 0.67; 2.68; p = 0.40).
The presence of non-criteria features is important to consider, as they are associated with particular clinical and laboratory profiles, increased risk of relapse, and need for additional therapies. Prospective studies are necessary to better stratify the prognosis and the management of p-APS.
•ANA positivity in patients with primary APS enables to individualize a subset of patients with a more severe phenotype.•ANA positivity does not seem to be associated with the risk to develop ...SLE.•Prospective studies with a longer follow-up are necessary, in particular to evaluate the effect of additional therapies in patients with ANA+ APS.
The antiphospholipid syndrome (APS) (1) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic autoimmune disease. The presence of ANA antibodies could confer a specific phenotype in primary APS.
To evaluate the characteristics of APS patients with antinuclear antibodies without other autoimmune disease (ANA positive APS patients) in comparison with primary APS without ANA or secondary APS patients with associated systemic lupus erythematosus (SLE).
Clinical and biologic data from 195 APS were retrospectively collected and patients were classified as primary APS with positive ANA (ANA-positive APS), primary APS without any ANA (ANA-negative APS), and SLE-associated APS (SLE-APS).
Fourty patients (21%) were classified into ANA-positive APS group, 77 (39%) in ANA-negative APS and 78 (40%) in SLE-APS. In ANA-positive APS patients, 20 patients (51%) had arterial thrombosis, 14 (41%) had veinous thrombosis and 19% had obstetrical complications. There was no difference between the three groups for the frequency of thrombotic manifestations and obstetrical complications. ANA-positive APS patients had more non-criteria manifestations than ANA-negative APS (48% versus 25%; P≤0.01). ANA-positive APS had more triple aPL positivity (59% versus 18%; P<0.001) and more thrombosis and obstetrical recurrences (63% versus 36%; P<0.01) in comparison with ANA-negative APS patients. ANA-positive APS had more triple aPL positivity than SLE-APS patients (54% versus 33%; P<0.05). ANA-positive APS and SLE-APS patients had similar clinical manifestations, and recurrences. Despite a limited follow-up (28 months (11–50)) none of the ANA-positive APS develop SLE. Antiplatelet and anticoagulant therapies were similar for the three groups. SLE-APS patients received more immunomodulatory therapies.
ANA positivity in patients with APS enables to individualize a subset of patients with a more severe phenotype. Whereas the ANA positivity does not seem to be associated with the risk to develop SLE, prospective studies with a longer follow-up are necessary, in particular to evaluate the effect of additional therapies in this subset of APS.
PDF
